COVID-19 and Antipsychotic Therapy: Unraveling the Thrombosis Risk
-
Published:2024-01-09
Issue:2
Volume:25
Page:818
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Dho-Nagy Eszter-Anna1, Brassai Attila1, Lechsner Patrick1, Ureche Corina2, Bán Erika-Gyöngyi1ORCID
Affiliation:
1. Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine in English, Preclinical Research Laboratory, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania 2. Department of Internal Medicine, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania
Abstract
In the context of the COVID-19 pandemic, this study investigates the potential correlation between the increased use of antipsychotic medications and the rising incidence of venous thromboembolism (VTE). As psychiatric disorders surged, the consequential escalation in antipsychotic drug use raised concerns about thrombotic risks. We conducted a comprehensive literature review using PubMed, focusing on articles that intersected COVID-19, antipsychotic medication, and thrombosis. This approach allowed for a nuanced examination of the historical and recent data on antipsychotic drugs and their association with thrombotic events. Our findings reveal a notable link between the use of antipsychotic medications, particularly second-generation antipsychotics, and an increased risk of VTE, including pulmonary embolism and deep vein thrombosis. This association was evident, despite variations in study designs and populations. The study underscores the need for cautious medication management in psychiatric care, especially during pandemic conditions like COVID-19, to mitigate thrombotic risks. It advocates a personalized approach to prescribing antipsychotics, considering individual patient factors and comorbidities, to balance the benefits against potential thrombotic complications.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference90 articles.
1. Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications;Harrison;Pharmacol. Res.,2021 2. Bliek-Bueno, K., Mucherino, S., Poblador-Plou, B., González-Rubio, F., Aza-Pascual-Salcedo, M., Orlando, V., Clerencia-Sierra, M., Ioakeim-Skoufa, I., Coscioni, E., and Carmona-Pírez, J. (2021). Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy. Int. J. Environ. Res. Public Health, 18. 3. Management of cancer-associated thromboembolism in vulnerable population;Laporte;Arch. Cardiovasc. Dis.,2024 4. Home treatment for patients with cancer-associated venous thromboembolism;Sanchez;Arch. Cardiovasc. Dis.,2024 5. Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment;Pavlovic;Clin. Med. Insights Oncol.,2023
|
|